Parkinson’s Disease Treatment Market To $7.58 Billion By 2030

Parkinson’s Disease Treatment Market Growth & Trends

The global parkinson’s disease treatment market size is expected to reach USD 7.58 billion by 2030, registering a CAGR of 5.04% from 2025 to 2030, according to a new report by Grand View Research, Inc. This can be attributed to the rising investment in the research and development of novel treatments for PD. In August 2021, the Parkinson’s Foundation announced an investment of USD 43 million as a research grant to 29 research projects having the goal of developing novel treatments and therapies for PD. In addition, in May 2021, the Parkinson’s Foundation announced an investment of USD 10 million for research, care, and educational programs related to Parkinson’s Disease (PD). This investment may aid in providing awareness and genetic testing free of cost to people suffering from PD.

Such investment initiatives are expected to boost industry growth. In the last ten years, there have been significant R&D activities in the PD therapy sector, leading to the development of innovative drug-delivery methods. Due to fewer side effects, these cutting-edge drug delivery systems outperform the existing ones. In addition, the rate of prescription for these techniques has increased due to a rise in patient compliance, which is fueling the expansion of the industry. Moreover, key pharmaceutical companies are undertaking initiatives, such as collaborations and partnerships, for the development, manufacturing & commercialization of products to meet the rising demand for disease treatment in the international market.

For instance, in November 2021, STADA Arzneimittel and Bioglan formed a partnership to expand the production capacity of the medicine Lecigon (levodopa/carbidopa/entacapone) used to treat patients with PD. Thus, increasing demand for medicines that are used to treat patients with PD is anticipated to drive industry growth. However, the limited availability of neurologists leads to issues, such as longer waiting times for patients and difficulty in hiring new neurosurgeons in hospitals. In addition, some of the currently practicing neurologists avoid accepting new Medicaid patients, which creates difficulty for patients who want to switch to another doctor. According to the American Academy of Neurology (AAN) report, around 19% shortage of neurologists is projected by 2025.

 Request a free sample copy or view report summary: Parkinson’s Disease Treatment Market Report

Parkinson’s Disease Treatment Market Report Highlights

• The carbidopa-levodopa segment dominated the Parkinson’s disease treatment industry and accounted for the largest revenue share of 25.12% in 2024 due to its long-established efficacy in managing symptoms, particularly tremors, stiffness, and bradykinesia.

• The retail pharmacy segment dominated the Parkinson’s disease treatment market with the revenue share of 41.59% in 2024 and is anticipated to witness the fastest growth over the forecast period due to its widespread accessibility and convenience for patients.

• North America dominated the Parkinson’s disease treatment market with a revenue share of 38.03% in 2024 due to a combination of factors such as a high prevalence of the disease, advanced healthcare infrastructure, and significant research and development investments.

• The Asia Pacific Parkinson’s disease treatment industry is experiencing rapid growth, attributed to rising healthcare expenditure, an aging population, and increased consumer awareness of neurological health.

Parkinson’s Disease Treatment Market Segmentation

Grand View Research has segmented global Parkinson’s disease treatment market report based on drug class, distribution channel, and region:

Parkinson’s Disease Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Carbidopa-Levodopa

• Dopamine Agonists

• MAO-B Inhibitors

• COMT inhibitors

• Anticholinergics

• Others

Parkinson’s Disease Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

Parkinson’s Disease Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Parkinson’s Disease Treatment Market

• Cerevel Therapeutics

• Novartis AG

• Teva Pharmaceutical Industries Ltd.

• Merck & Co., Inc.

• GlaxoSmithKline plc. (GSK)

• AbbVie, Inc.

• H. Lundbeck A/S

• Amneal Pharmaceuticals LLC

• Supernus Pharmaceuticals, Inc.